The minimal impact of food on the pharmacokinetics of ridaforolimus

Abstract

Ridaforolimus, a potent inhibitor of the mammalian target of rapamycin (mTOR), is under development for the treatment for solid tumors. This open-label, randomized, 3-period crossover study investigated the effect of food on the pharmacokinetics of ridaforolimus 40 mg as well as safety and tolerability of the study medication. Ridaforolimus was administered… (More)
DOI: 10.1007/s00280-012-1897-8

Topics

2 Figures and Tables

Slides referencing similar topics